3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
durvalumab
3
abemaciclib
2
Pemetrexed
2
Fulvestrant
2
Cisplatin
2
Carboplatin
2
ribociclib
1
repotrectinib
1
pembrolizumab
1
palbociclib
1
exemestane
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
RAD1901
1
Nivolumab
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Drug Therapy
1
Docetaxel
1
Bevacizumab
1
Anastrozole
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Immunotherapy
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled